A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 41
- Registration Number
- NCT02421211
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 24
- Registration Number
- NCT02398591
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 66
- Registration Number
- NCT02387606
A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment EDrug: Treatment C
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 48
- Registration Number
- NCT02385071
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 145
- Registration Number
- NCT01281813
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 46
- Registration Number
- NCT01138605
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 180
- Registration Number
- NCT00980538
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
Phase 2
Completed
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
© Copyright 2025. All Rights Reserved by MedPath